Ativan Shortage: A Provider Briefing for 2026

Lorazepam — marketed as Ativan — has been subject to intermittent supply disruptions that continue to affect patient access in 2026. For prescribers across psychiatry, primary care, neurology, and emergency medicine, these availability challenges have practical implications for treatment planning, prescribing decisions, and patient communication.

This briefing covers the current state of Lorazepam availability, the factors driving supply issues, prescribing considerations, cost and access data, and tools that can help your patients locate their medication.

Timeline of the Lorazepam Shortage

Lorazepam supply issues have evolved over several years:

• 2016-2019: The FDA first listed Lorazepam injection on its Drug Shortage Database due to manufacturing delays at key producers. Oral tablet supply remained relatively stable during this period.
• 2020-2022: The COVID-19 pandemic drove a significant increase in benzodiazepine prescribing for anxiety and sleep disorders. Lorazepam prescriptions rose alongside the broader class. Supply chain disruptions — including API sourcing delays and international manufacturing issues — began affecting oral tablet availability.
• 2023-2024: Oral tablet supply became inconsistent across regions. Certain strengths and manufacturers experienced back orders. Teva's 0.5 mg tablets were notably affected. The injectable form continued to face shortages, with Hikma (the manufacturer of brand-name Ativan injection) experiencing production delays.
• 2025-2026: Supply has gradually improved but remains uneven. Multiple generic manufacturers are producing oral tablets, but distribution is inconsistent — some pharmacies have adequate stock while others face recurring gaps. The injectable shortage has shown improvement, with Hikma estimating resupply of several products in late 2025.

Prescribing Implications

The intermittent nature of the Lorazepam shortage creates several considerations for prescribers:

Prescription Fillability

Patients may present with difficulty filling Lorazepam prescriptions, particularly at chain pharmacies. This is often a distribution issue rather than a true manufacturing shortage — the medication is being produced, but not uniformly available at the point of dispensing.

Consider the following when writing prescriptions:

• Specify "generic Lorazepam" rather than brand-name Ativan to give pharmacies maximum flexibility in sourcing from available manufacturers.
• Be open to strength substitutions: If 2 mg tablets are unavailable, prescribing two 1 mg tablets achieves the same dose with potentially better availability.
• Include DAW 0 (Dispense as Written — substitution permitted) to allow the pharmacist to fill from any available generic manufacturer.

Therapeutic Alternatives

When Lorazepam is consistently unavailable for a specific patient, equivalent-dose substitutions within the benzodiazepine class are the most straightforward approach:

• Alprazolam (Xanax): 0.5 mg Alprazolam ≈ 1 mg Lorazepam. Shorter duration; may be preferable for panic disorder but carries higher rebound risk.
• Clonazepam (Klonopin): 0.25-0.5 mg Clonazepam ≈ 1 mg Lorazepam. Longer duration (18-50 hour half-life); useful for patients who benefit from more stable plasma levels.
• Diazepam (Valium): 5 mg Diazepam ≈ 1 mg Lorazepam. Very long-acting with active metabolites; preferred for alcohol withdrawal protocols. Use caution in hepatic impairment.

For patients where benzodiazepine alternatives are also unavailable or where tapering is clinically appropriate:

• Hydroxyzine (Vistaril): 25-50 mg PRN for acute anxiety. Non-controlled, no dependence risk. Less effective for severe anxiety or seizure prophylaxis.
• Buspirone: 5-15 mg TID for chronic generalized anxiety. 2-4 week onset; not useful for acute symptoms.

For a patient-facing comparison, you may direct patients to our article on alternatives to Ativan.

Current Availability Picture

As of early 2026, the Lorazepam supply situation can be summarized as follows:

• Oral tablets (0.5 mg, 1 mg, 2 mg): Being produced by Teva, Actavis, Mylan, Leading Pharma, and others. Availability varies by region and pharmacy. Independent pharmacies with access to multiple wholesalers tend to have better stock consistency.
• Oral concentrate (Lorazepam Intensol, 2 mg/mL): Generally available but not widely stocked by retail pharmacies. May need to be special-ordered.
• Injectable (2 mg/mL and 4 mg/mL): Improving but still subject to intermittent back orders. Hikma projected resupply for several SKUs in late 2025. Hospital formulary committees should monitor ASHP drug shortage updates.

Cost and Access

Generic Lorazepam remains an affordable medication, which is helpful for patient access:

• Insured patients: Most commercial and Medicare plans cover generic Lorazepam on Tier 1 with $0-$10 copays. Prior authorization is generally not required for the generic.
• Uninsured/underinsured patients: Retail cash price is $8-$30 for a 30-day supply. Discount cards (GoodRx, SingleCare) can reduce this to $3-$10.
• Brand-name Ativan: $200+ for a 30-day supply. Rarely cost-effective given generic availability.

There are no manufacturer savings programs or patient assistance programs (PAPs) specifically for Lorazepam, as it is available only as a generic. For cost-saving strategies to share with patients, see how to save money on Ativan.

Tools and Resources for Your Practice

Several tools can help you and your patients navigate Lorazepam availability:

• Medfinder for Providers: A free tool that shows real-time medication availability at pharmacies. Share this with patients who are having trouble locating Lorazepam, or use it in your workflow to direct patients to pharmacies with current stock.
• ASHP Drug Shortage Database: The American Society of Health-System Pharmacists maintains up-to-date shortage information, including estimated resupply dates and therapeutic alternatives. Essential for hospital and inpatient settings.
• FDA Drug Shortage Database: Federal shortage tracking with manufacturer-level detail on production status.

For a provider-specific guide to helping patients find medications during shortages, see our article on how to help your patients find Ativan in stock.

Looking Ahead

The Lorazepam supply situation is expected to continue improving through 2026, but intermittent disruptions are likely to persist. Key factors to watch:

• DEA quota adjustments: The DEA periodically reviews and adjusts manufacturing quotas for controlled substances. Increased quotas could help alleviate supply pressure.
• Generic manufacturer capacity: With multiple companies producing Lorazepam, the supply base is broad. However, consolidation in the generic pharmaceutical industry means that disruptions at any single manufacturer can have outsized effects.
• Prescribing trends: If benzodiazepine prescribing rates stabilize or decline — as some data suggests with increased adoption of non-benzodiazepine anxiolytics and therapy-based approaches — demand pressure may ease.

Final Thoughts

The Lorazepam shortage is primarily a distribution challenge rather than a production crisis. Oral tablets are being manufactured, but availability varies by pharmacy, region, and specific strength. Prescribers can help patients navigate this by being flexible with strengths and formulations, guiding patients toward pharmacies with better sourcing capabilities, and having alternative treatment plans ready when Lorazepam is unavailable.

For clinical questions about Lorazepam pharmacology, interactions, and side effect management, see our articles on how Ativan works and Ativan drug interactions.

For cost-related guidance to share with patients, our provider's guide to helping patients save money on Ativan covers discount programs, assistance options, and practical strategies.